Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. 2017

Kilannin Krysiak, and Felicia Gomez, and Brian S White, and Matthew Matlock, and Christopher A Miller, and Lee Trani, and Catrina C Fronick, and Robert S Fulton, and Friederike Kreisel, and Amanda F Cashen, and Kenneth R Carson, and Melissa M Berrien-Elliott, and Nancy L Bartlett, and Malachi Griffith, and Obi L Griffith, and Todd A Fehniger
McDonnell Genome Institute, Department of Medicine.

Follicular lymphoma (FL) is the most common form of indolent non-Hodgkin lymphoma, yet it remains only partially characterized at the genomic level. To improve our understanding of the genetic underpinnings of this incurable and clinically heterogeneous disease, whole-exome sequencing was performed on tumor/normal pairs from a discovery cohort of 24 patients with FL. Using these data and mutations identified in other B-cell malignancies, 1716 genes were sequenced in 113 FL tumor samples from 105 primarily treatment-naive individuals. We identified 39 genes that were mutated significantly above background mutation rates. CREBBP mutations were associated with inferior PFS. In contrast, mutations in previously unreported HVCN1, a voltage-gated proton channel-encoding gene and B-cell receptor signaling modulator, were associated with improved PFS. In total, 47 (44.8%) patients harbor mutations in the interconnected B-cell receptor (BCR) and CXCR4 signaling pathways. Histone gene mutations were more frequent than previously reported (identified in 43.8% of patients) and often co-occurred (17.1% of patients). A novel, recurrent hotspot was identified at a posttranslationally modified residue in the histone H2B family. This study expands the number of mutated genes described in several known signaling pathways and complexes involved in lymphoma pathogenesis (BCR, Notch, SWitch/sucrose nonfermentable (SWI/SNF), vacuolar ATPases) and identified novel recurrent mutations (EGR1/2, POU2AF1, BTK, ZNF608, HVCN1) that require further investigation in the context of FL biology, prognosis, and treatment.

UI MeSH Term Description Entries
D007473 Ion Channels Gated, ion-selective glycoproteins that traverse membranes. The stimulus for ION CHANNEL GATING can be due to a variety of stimuli such as LIGANDS, a TRANSMEMBRANE POTENTIAL DIFFERENCE, mechanical deformation or through INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS. Membrane Channels,Ion Channel,Ionic Channel,Ionic Channels,Membrane Channel,Channel, Ion,Channel, Ionic,Channel, Membrane,Channels, Ion,Channels, Ionic,Channels, Membrane
D008224 Lymphoma, Follicular Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES. Brill-Symmers Disease,Follicular Lymphoma,Lymphoma, Giant Follicular,Lymphoma, Nodular,Follicular Large-Cell Lymphoma,Follicular Lymphoma, Giant,Follicular Lymphoma, Grade 1,Follicular Lymphoma, Grade 2,Follicular Lymphoma, Grade 3,Follicular Mixed-Cell Lymphoma,Giant Follicular Lymphoma,Histiocytic Lymphoma, Nodular,Large Lymphoid Lymphoma, Nodular,Large-Cell Lymphoma, Follicular,Lymphocytic Lymphoma, Nodular, Poorly Differentiated,Lymphocytic Lymphoma, Nodular, Poorly-Differentiated,Lymphoma, Follicular Large-Cell,Lymphoma, Follicular, Grade 1,Lymphoma, Follicular, Grade 2,Lymphoma, Follicular, Grade 3,Lymphoma, Follicular, Mixed Cell,Lymphoma, Follicular, Mixed Lymphocytic-Histiocytic,Lymphoma, Follicular, Mixed Small and Large Lymphoid,Lymphoma, Follicular, Small and Large Cleaved Cell,Lymphoma, Follicular, Small and Large Cleaved-Cell,Lymphoma, Histiocytic, Nodular,Lymphoma, Large Cell, Follicular,Lymphoma, Large Lymphoid, Nodular,Lymphoma, Large-Cell, Follicular,Lymphoma, Lymphocytic, Nodular, Poorly Differentiated,Lymphoma, Lymphocytic, Nodular, Poorly-Differentiated,Lymphoma, Mixed-Cell, Follicular,Lymphoma, Nodular, Large Follicular Center Cell,Lymphoma, Nodular, Large Follicular Center-Cell,Lymphoma, Nodular, Mixed Lymphocytic Histiocytic,Lymphoma, Nodular, Mixed Lymphocytic-Histiocytic,Lymphoma, Nodular, Mixed Small and Large Cell,Lymphoma, Small Cleaved Cell, Follicular,Lymphoma, Small Cleaved-Cell, Follicular,Lymphoma, Small Follicular Center-Cell,Lymphoma, Small Lymphoid, Follicular,Mixed-Cell Lymphoma, Follicular,Nodular Large Follicular Center-Cell Lymphoma,Small Cleaved-Cell Lymphoma, Follicular,Small Follicular Center-Cell Lymphoma,Brill Symmers Disease,Disease, Brill-Symmers,Follicular Large Cell Lymphoma,Follicular Large-Cell Lymphomas,Follicular Lymphomas,Follicular Lymphomas, Giant,Follicular Mixed Cell Lymphoma,Follicular Mixed-Cell Lymphomas,Giant Follicular Lymphomas,Histiocytic Lymphomas, Nodular,Large Cell Lymphoma, Follicular,Large-Cell Lymphomas, Follicular,Lymphoma, Follicular Large Cell,Lymphoma, Follicular Mixed-Cell,Lymphoma, Nodular Histiocytic,Lymphoma, Small Follicular Center Cell,Lymphomas, Follicular,Lymphomas, Follicular Large-Cell,Lymphomas, Follicular Mixed-Cell,Lymphomas, Giant Follicular,Lymphomas, Nodular,Lymphomas, Nodular Histiocytic,Mixed Cell Lymphoma, Follicular,Mixed-Cell Lymphomas, Follicular,Nodular Histiocytic Lymphoma,Nodular Histiocytic Lymphomas,Nodular Large Follicular Center Cell Lymphoma,Nodular Lymphoma,Nodular Lymphomas,Small Cleaved Cell Lymphoma, Follicular,Small Follicular Center Cell Lymphoma
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011947 Receptors, Antigen, B-Cell IMMUNOGLOBULINS on the surface of B-LYMPHOCYTES. Their MESSENGER RNA contains an EXON with a membrane spanning sequence, producing immunoglobulins in the form of type I transmembrane proteins as opposed to secreted immunoglobulins (ANTIBODIES) which do not contain the membrane spanning segment. Antigen Receptors, B-Cell,B-Cell Antigen Receptor,B-Cell Antigen Receptors,Surface Immunoglobulin,Immunoglobulins, Membrane-Bound,Immunoglobulins, Surface,Membrane Bound Immunoglobulin,Membrane-Bound Immunoglobulins,Receptors, Antigen, B Cell,Surface Immunoglobulins,Antigen Receptor, B-Cell,Antigen Receptors, B Cell,B Cell Antigen Receptor,B Cell Antigen Receptors,Bound Immunoglobulin, Membrane,Immunoglobulin, Membrane Bound,Immunoglobulin, Surface,Immunoglobulins, Membrane Bound,Membrane Bound Immunoglobulins,Receptor, B-Cell Antigen,Receptors, B-Cell Antigen
D012097 Repressor Proteins Proteins which maintain the transcriptional quiescence of specific GENES or OPERONS. Classical repressor proteins are DNA-binding proteins that are normally bound to the OPERATOR REGION of an operon, or the ENHANCER SEQUENCES of a gene until a signal occurs that causes their release. Repressor Molecules,Transcriptional Silencing Factors,Proteins, Repressor,Silencing Factors, Transcriptional
D005260 Female Females
D006657 Histones Small chromosomal proteins (approx 12-20 kD) possessing an open, unfolded structure and attached to the DNA in cell nuclei by ionic linkages. Classification into the various types (designated histone I, histone II, etc.) is based on the relative amounts of arginine and lysine in each. Histone,Histone H1,Histone H1(s),Histone H2a,Histone H2b,Histone H3,Histone H3.3,Histone H4,Histone H5,Histone H7

Related Publications

Kilannin Krysiak, and Felicia Gomez, and Brian S White, and Matthew Matlock, and Christopher A Miller, and Lee Trani, and Catrina C Fronick, and Robert S Fulton, and Friederike Kreisel, and Amanda F Cashen, and Kenneth R Carson, and Melissa M Berrien-Elliott, and Nancy L Bartlett, and Malachi Griffith, and Obi L Griffith, and Todd A Fehniger
July 2022, Cancers,
Kilannin Krysiak, and Felicia Gomez, and Brian S White, and Matthew Matlock, and Christopher A Miller, and Lee Trani, and Catrina C Fronick, and Robert S Fulton, and Friederike Kreisel, and Amanda F Cashen, and Kenneth R Carson, and Melissa M Berrien-Elliott, and Nancy L Bartlett, and Malachi Griffith, and Obi L Griffith, and Todd A Fehniger
September 2016, Clinical chemistry,
Kilannin Krysiak, and Felicia Gomez, and Brian S White, and Matthew Matlock, and Christopher A Miller, and Lee Trani, and Catrina C Fronick, and Robert S Fulton, and Friederike Kreisel, and Amanda F Cashen, and Kenneth R Carson, and Melissa M Berrien-Elliott, and Nancy L Bartlett, and Malachi Griffith, and Obi L Griffith, and Todd A Fehniger
November 2020, International journal of molecular sciences,
Kilannin Krysiak, and Felicia Gomez, and Brian S White, and Matthew Matlock, and Christopher A Miller, and Lee Trani, and Catrina C Fronick, and Robert S Fulton, and Friederike Kreisel, and Amanda F Cashen, and Kenneth R Carson, and Melissa M Berrien-Elliott, and Nancy L Bartlett, and Malachi Griffith, and Obi L Griffith, and Todd A Fehniger
April 2014, Nature genetics,
Kilannin Krysiak, and Felicia Gomez, and Brian S White, and Matthew Matlock, and Christopher A Miller, and Lee Trani, and Catrina C Fronick, and Robert S Fulton, and Friederike Kreisel, and Amanda F Cashen, and Kenneth R Carson, and Melissa M Berrien-Elliott, and Nancy L Bartlett, and Malachi Griffith, and Obi L Griffith, and Todd A Fehniger
November 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Kilannin Krysiak, and Felicia Gomez, and Brian S White, and Matthew Matlock, and Christopher A Miller, and Lee Trani, and Catrina C Fronick, and Robert S Fulton, and Friederike Kreisel, and Amanda F Cashen, and Kenneth R Carson, and Melissa M Berrien-Elliott, and Nancy L Bartlett, and Malachi Griffith, and Obi L Griffith, and Todd A Fehniger
August 1987, Acta paediatrica Japonica : Overseas edition,
Kilannin Krysiak, and Felicia Gomez, and Brian S White, and Matthew Matlock, and Christopher A Miller, and Lee Trani, and Catrina C Fronick, and Robert S Fulton, and Friederike Kreisel, and Amanda F Cashen, and Kenneth R Carson, and Melissa M Berrien-Elliott, and Nancy L Bartlett, and Malachi Griffith, and Obi L Griffith, and Todd A Fehniger
May 2018, Oncotarget,
Kilannin Krysiak, and Felicia Gomez, and Brian S White, and Matthew Matlock, and Christopher A Miller, and Lee Trani, and Catrina C Fronick, and Robert S Fulton, and Friederike Kreisel, and Amanda F Cashen, and Kenneth R Carson, and Melissa M Berrien-Elliott, and Nancy L Bartlett, and Malachi Griffith, and Obi L Griffith, and Todd A Fehniger
April 2022, Blood,
Kilannin Krysiak, and Felicia Gomez, and Brian S White, and Matthew Matlock, and Christopher A Miller, and Lee Trani, and Catrina C Fronick, and Robert S Fulton, and Friederike Kreisel, and Amanda F Cashen, and Kenneth R Carson, and Melissa M Berrien-Elliott, and Nancy L Bartlett, and Malachi Griffith, and Obi L Griffith, and Todd A Fehniger
February 2018, Scientific reports,
Kilannin Krysiak, and Felicia Gomez, and Brian S White, and Matthew Matlock, and Christopher A Miller, and Lee Trani, and Catrina C Fronick, and Robert S Fulton, and Friederike Kreisel, and Amanda F Cashen, and Kenneth R Carson, and Melissa M Berrien-Elliott, and Nancy L Bartlett, and Malachi Griffith, and Obi L Griffith, and Todd A Fehniger
February 2016, Nature genetics,
Copied contents to your clipboard!